Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

From Netanya labs to global race: Teva develops antibody targeting celiac and autoimm

Summary by Ynet News
Backed by up to $500 million deal, Teva advances experimental antibody for celiac and vitiligo, aiming to stop autoimmune disease at its source; researcher offers rare look inside complex path from lab to patients

1 Articles

Ynet NewsYnet News
Lean Left

From Netanya labs to global race: Teva develops antibody targeting celiac and autoimm

Backed by up to $500 million deal, Teva advances experimental antibody for celiac and vitiligo, aiming to stop autoimmune disease at its source; researcher offers rare look inside complex path from lab to patients

·Tel Aviv-Yafo, Israel
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Ynet News broke the news in Tel Aviv-Yafo, Israel on Tuesday, April 7, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Netanya icon

Netanya

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal